b'Edgewise Therapeutics Aligns Scientific Clarity With Patient NeedEdgewise Therapeutics started with a cleanBoulder is an incredible place to live, slate and a singular focus on serious skeletal and cardiac muscle diseases, conditions whereand our scientists want to live and there are few or no treatments available.We had a blank sheet of paper, said cofounderwork somewhere amazing.and Chief Scientific Officer Alan Russell, Ph.D. We couldve gone anywhere.ALAN RUSSELL, Ph.D.At first, all signs pointed toward the Bay Area,COFOUNDER & CSObut the founders, including serial entrepre- EDGEWISE THERAPEUTICSneur Kevin Koch, Ph.D., made a deliberate pivot to Boulder. It is an incredible place to live, and our scientists want to live and work somewhere amazing. You also have the University of Colorado Boulder here and the University of Colorado Anschutz Medical Campus down the road, said Russell.Formed by industry veterans with experience at GSK, Cytokinetics, Array BioPharma, and Biogen, the company focuses on diseases with devastating impacts like muscular dystrophy and cardiovascular disease. Edgewise caught the attention of investors, generating $200 million in its initial public offering in April 2021. Their velocity is inspiring, as Edgewise shared positive data in June 2025 from its sevasemten program showing sustained functional benefits in Becker muscular dystrophy and promising early results in Duchenne muscular dystrophy. The FDA outlined a clear path for potentialengage with the patient community enough. sevasemten registration as the first-ever therapyYou have to make the best thing that you can for Becker, with key data from another trialmake, the community has to be aware of it, expected in late 2026.and also tell you what they need from it.Earlier this year, the company also releasedThis patient-first culture shapes everything the promising preliminary Phase 2 data in theircompany does, from how trials are designed to CV program of EDG-7500 in individuals livingendpoint selection to how the team engages with hypertrophic cardiomyopathy. Edgewisewith those impacted by the diseases Edgewise hopes EDG-7500, created in their Boulder lab,focuses on. will become a promising new way to treat theEdgewise Therapeutics was most common inherited heart disease.When the team connects with patients livinghonored as Company of the with Becker muscular dystrophy, patientsYear at CBSAs 21 stAnnual Since its earliest days, the team made aand their families often say that years passAwards Celebration.deliberate decision to integrate the patientwithout medical intervention because no perspective into their research. effective treatment exists. Thats why Edgewise Our Head of Advocacy was employee numberis motivated to create a future where patients eleven, Russell shared. That was intentional.are met with meaningful care, decisive action, Weve seen how other companies dontand real therapeutic hope.8 BIOSCIENCE COLORADO 2025-2026'